July 17, 2017 / 11:15 AM / 4 days ago

BRIEF-Apexigen doses first patient in combo trial for advanced solid tumors

1 Min Read

July 17 (Reuters) -

* Apexigen, Inc. Announces first patient dosed in phase 1b/2 clinical trial of apx005m in combination with opdivo (nivolumab) in advanced solid tumors Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below